Singapur - anglès - HSA (Health Sciences Authority)

novo nordisk pharma (singapore) pte ltd - liraglutide - injection, solution - 6mg/ml - liraglutide 6mg/ml

Malàisia - anglès - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novo nordisk pharma (malaysia) sdn. bhd. - liraglutide; insulin degludec -

Israel - anglès - Ministry of Health

novo nordisk ltd., israel - liraglutide - solution for injection - liraglutide 6 mg / 1 ml - liraglutide - adultssaxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (bmi) of •≥30 kg/m² (obesity), or •≥27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension or dyslipidaemia, and who have failed a previous weight management intervention. treatment with saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight.adolescents (≥12 years)saxenda can be used as an adjunct to a healthy nutrition and increased physical activity for weight management in adolescent patients from the age of 12 years and above with:• obesity (bmi corresponding to ≥30 kg/m2 for adults by international cut-off points)* and• body weight above 60 kg. treatment with saxenda should be discontinued and re-evaluated if patients have not lost at least 4% of their bmi or bmi z score after 12 weeks on the 3.0 mg/day or maximum tolerated dose. re-evaluation should be performed periodically

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

colorama pharmaceuticals ltd - liraglutide - solution for injection - 6mg/1ml

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

j m mcgill ltd - liraglutide - solution for injection - 6mg/1ml

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

niche pharma ltd - liraglutide - solution for injection - 6mg/1ml

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - liraglutide - solution for injection - 6mg/1ml

Armènia - anglès - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

novo nordisk a/s - liraglutide - solution for s/c injection - 6mg/ml

Armènia - anglès - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

novo nordisk a/s - liraglutide - solution for s/c injection - 6mg/ml

Unió Europea - anglès - EMA (European Medicines Agency)

novo nordisk a/s - liraglutide - diabetes mellitus, type 2 - drugs used in diabetes - victoza is indicated for the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes.for study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied.